Mainz, December 21, 2012 – The TRON labs and offices are closed December 22 through January 1.
Mainz, December 21, 2012 – TRON is whishing all of its partners and friends happy holidays and a successful New Year 2013.
Mainz, December 13, 2012 – “Challenges and opportunities of a next generation dendritic cell cancer vaccine: pre-clinical and clinical overview” with Prof. Dr. Ada Kruisbeek, Founder and CSO of DCprime BV, Leiden, Netherlands
Mainz, November 22, 2012 – “Making biomarkers functional – a path towards personalized medicine” with Dr. Matthew L. Albert, Director of Research INSERM and Head of the Laboratory of Dendritic Cell Immunobiology at the Institut Pasteur, Paris
TRON participates with posters and presentations Mainz, Germany, November 19, 2012 – On December 5, the Cluster for Individualized ImmunIntervention (CI-3) hosts a conference for participating partners and networks to present all projects sponsored by the German Federal Ministry of Education and Research. The meeting will take place at Kurfürstliches Schloss in Mainz and…
Mainz, November 15, 2012 – “Role of BCL9 proteins in Wnt-mediated stem cell maintenance” with Prof. Dr. Michel Aguet, National Center of Competence in Research (NCCR) “Molecular Oncology”, Lausanne, Switzerland
Mainz, October 11, 2012 – 5 p.m. “Tetramere validation and new targets in oncology” with Ronald Rooke, Transgene SA, Illkirch Graffenstaden Cedex, France
Mainz, Germany, October 2, 2012 – TRON scientists have pioneered a statistical framework that enables researchers to reduce the number of false discovery rates for tumor mutations. The method was published in the September issue of PLOS Computational Biology. While next generation sequencing (NGS) has enabled the highly accurate, unbiased, and high throughput discovery of
Mainz, October 5, 2012 (Change of date!) – 2 p.m. “Dissecting cytotoxic T cell immunity in mice and men” with Prof. Dr. Ton Schumacher, Head of Immunology, Netherlands Cancer Institute, Netherlands
Mainz, Germany, September 6, 2012 – The emerging era of individualized cancer immunotherapy is dramatically changing the target landscape by adding targets that can be recognized by antibodies and T cells, thus significantly increasing the number of druggable tumor targets. In a recent article in the European Pharmaceutical Review, TRON scientists describe a process to
Mainz, September 6, 2012 – CANCELLED due to Lufthansa strike. Seminar will now take place on 15th November 2012! “Role of BCL9 proteins in Wnt-mediated stem cell maintenance” with Prof. Dr. Michel Aguet, National Center of Competence in Research (NCCR) “Molecular Oncology”, Lausanne, Switzerland